[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483642":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All patients",null,"There is only one arm in the trial",[13],"Other: Tissue",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Tissue","Tissue will be derived from patients during a standard of care procedure",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Yao Zhu","CONTACT","+86 15001818005","mailzhuyao@163.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":42,"phoneExt":10,"email":43},"Yao Zhu, MD","+8615001818005","zhuyao@fudan.edu.cn",{"type":45,"investigatorFullName":46,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ding-Wei Ye","100483642","novel-therapy-target-in-metastatic-prostate-cancer-100483642",false,"NCT05577689","Novel Therapy Target in Metastatic Prostate Cancer","Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer","NTTPro","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer\n2. metastatic disease confirmed by image examination\n3. Patients who can undergo surgery or biopsy for prostate cancer\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Patients diagnosed with other types of cancer besides prostate cancer\n2. Not accessible to surgery sample\n3. Patients fail to provide informed consent\n4. Other situation that researchers think are unsuitable for this study","MALE","18 Years",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.",[63],"Prostate Neoplasms",[65,66,67],"prostate cancer","multi-omics","organoid","2025-06-01",{"date":70,"type":71},"2025-06-05","ACTUAL",{"date":73,"type":71},"2023-08-01",{"date":75,"type":59},"2028-12-01",{"name":5,"class":6},1]